Format

Send to

Choose Destination
Curr Opin Mol Ther. 2006 Apr;8(2):156-63.

HuCNS-SC (StemCells).

Author information

1
National Neuroscience Institute, National University of Singapore, 11 Jalan Tan Tock Seng, Singapore. obgpjt@nus.edu.sg

Abstract

HuCNS-SC, a proprietary human neural stem cells product, is being developed as a cellular therapy for the potential treatment of Batten disease, one of a group of disorders known as neural ceroid lipofuscinoses (NCL). Developer StemCells is also investigating the therapy for spinal cord injury and other central nervous system disorders, such as demyelinating disease, stroke and Alzheimer's disease. A phase I trial of HuCNS-SC for infantile and late-infantile NCL has been initiated, following the March 2006 U.S. Food and Drug Administration approval of StemCells' investigational new drug application.

PMID:
16610769
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center